| Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy A Hochhaus, S Kreil, AS Corbin, P La Rosee, MC Müller, T Lahaye, ... Leukemia 16 (11), 2190-2196, 2002 | 1233 | 2002 |
| Recommendations for the management of hemophagocytic lymphohistiocytosis in adults P La Rosée, AC Horne, M Hines, T von Bahr Greenwood, R Machowicz, ... Blood, The Journal of the American Society of Hematology 133 (23), 2465-2477, 2019 | 791 | 2019 |
| Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the … AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... The Lancet Haematology 3 (5), e217-e227, 2016 | 530 | 2016 |
| Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) P La Rosée, AS Corbin, EP Stoffregen, MW Deininger, BJ Druker Cancer research 62 (24), 7149-7153, 2002 | 311 | 2002 |
| Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS … AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, P La Rosée, ... The Lancet Haematology 4 (11), e510-e523, 2017 | 308 | 2017 |
| Lack of clinical efficacy of imatinib in metastatic melanoma S Ugurel, R Hildenbrand, A Zimpfer, P La Rosee, P Paschka, A Sucker, ... British journal of cancer 92 (8), 1398-1405, 2005 | 291 | 2005 |
| Current gaps in sepsis immunology: new opportunities for translational research I Rubio, MF Osuchowski, M Shankar-Hari, T Skirecki, MS Winkler, ... The Lancet infectious diseases 19 (12), e422-e436, 2019 | 271 | 2019 |
| The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation F La Rosée, HC Bremer, I Gehrke, A Kehr, A Hochhaus, S Birndt, ... Leukemia 34 (7), 1805-1815, 2020 | 227 | 2020 |
| Positron emission tomography–guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial U Dührsen, S Müller, B Hertenstein, H Thomssen, J Kotzerke, R Mesters, ... Journal of Clinical Oncology 36 (20), 2024-2034, 2018 | 205 | 2018 |
| A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adults N Daver, K McClain, CE Allen, SA Parikh, Z Otrock, C Rojas‐Hernandez, ... Cancer 123 (17), 3229-3240, 2017 | 203 | 2017 |
| Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies K Lehmberg, KE Nichols, JI Henter, M Girschikofsky, T Greenwood, ... Haematologica 100 (8), 997, 2015 | 189 | 2015 |
| Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib T Ernst, P Erben, MC Müller, P Paschka, T Schenk, J Hoffmann, S Kreil, ... Haematologica 93 (2), 186-192, 2008 | 155 | 2008 |
| Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the … S Ehl, I Astigarraga, T von Bahr Greenwood, M Hines, AC Horne, E Ishii, ... The Journal of Allergy and Clinical Immunology: In Practice 6 (5), 1508-1517, 2018 | 150 | 2018 |
| Detection and quantification of residual disease in chronic myelogenous leukemia A Hochhaus, A Weisser, P La Rosee, M Emig, MC Müller, S Saussele, ... Leukemia 14 (6), 998-1005, 2000 | 150 | 2000 |
| In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines P La Rosée, K Johnson, AS Corbin, EP Stoffregen, EM Moseson, S Willis, ... Blood 103 (1), 208-215, 2004 | 141 | 2004 |
| In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia P La Rosée, K Johnson, ME O'Dwyer, BJ Druker Experimental hematology 30 (7), 729-737, 2002 | 129 | 2002 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 126 | 2018 |
| Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma C Dierks, J Seufert, K Aumann, J Ruf, C Klein, S Kiefer, M Rassner, ... Thyroid 31 (7), 1076-1085, 2021 | 125 | 2021 |
| Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia … P La Rosee, ME O'Dwyer, BJ Druker Leukemia 16 (7), 1213-1219, 2002 | 119 | 2002 |
| Treatment of hemophagocytic lymphohistiocytosis in adults P La Rosée Hematology 2014, the American Society of Hematology Education Program Book …, 2015 | 115 | 2015 |
